- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07610538
Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells (Leuk-ALIVE)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
So far, our lab has looked at Tregs and immune cells in the blood. The question remained whether ld-IL-2 can have the desired effect on Tregs in tissues, particularly the vasculature and cardiac tissues, where they could promote tissue repair and potentially improve clinical outcomes for patients after a myocardial infarction which causes significant tissue damage. Clinically, this could lead to lower rates of heart failure.
In both the LILACS and IVORY trials, the effect measured was on circulating Tregs, whilst the effect of ld-IL-2 on tissue resident immune cells remains unknown.
Therefore, the aims of the study are to understand the effect of treatment with ld-IL-2 on tissue-resident immune cells in the context of ischaemic heart disease and acute MI where there has been acute tissue damage. This includes:
- Assessment if ld-IL-2, given systemically to patients at our proposed doses, can alter Tregs in the vasculature and cardiac tissues to exhibit a tissue repair and anti-inflammatory phenotype
- Studying the relationship between the vasculature, cardiac tissues and circulating immune cells after systemic ld-IL-2 administration.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Royaume-Uni, CB2 0QQ
- Recrutement
- Addenbrooke's Hospital
-
Contact:
- Ali Al-Hadithi, MB BChir
- Numéro de téléphone: 01223768678
- E-mail: abaka2@cam.ac.uk
-
Cambridge, Cambridgeshire, Royaume-Uni, CB2 0AY
- Recrutement
- Royal Papworth Hospital NHS Foundation Trust
-
Contact:
- Ali Al-Hadithi, MB BChir
- Numéro de téléphone: 01223768678 Royal Papworth Hospital NHS Fo
- E-mail: abaka2@cam.ac.uk
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Aged over 18 years old
- Undergoing CABG surgery
Exclusion Criteria:
- Critical left main stem coronary disease
- Severe valvular disease (for example 'severe' aortic stenosis as classified on echocardiogram report)
- Haemodynamic instability caused by arrhythmia requiring cardioversion in the current admission
- Non-sustained ventricular tachycardia of >10 beats in the last 48 hours
- Autoimmune disease
- Any regular immunosuppressive treatment [Inhaled or topical steroids are permissible]
- Known active hepatic disease or alanine aminotransferase (ALT) > 3xULN
- Severe chronic kidney disease (defined as eGFR < 30 ml/min/1.73m2)
- Allergy or intolerance to aldesleukin
- Signs and symptoms of active infection
- History of human immunodeficiency virus (HIV), hepatitis B or C
- Current malignancy requiring active treatment
- Vaccine within 4 weeks prior to screening
- Women of child-bearing potential and pregnancy (women must be either postmenopausal (defined as being amenorrhoeic for greater than 2 years with an appropriate clinical profile (e.g. age appropriate (>55 years old), history of vasomotor symptoms) or having documented hysterectomy and/or bilateral oophorectomy)
- Women who are breast-feeding
- Clinically relevant medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Contrôle
Traitement standard
|
Standard care for patients with coronary artery disease undergoing CABG surgery
|
|
Expérimental: Low dose interleukin-2 at dose 1.5MIU
Commercially available aldesleukin with a UK marketing authorisation will be used and will be initially prepared as per SmPC.
Dose of 1.5MIU will be used for all daily and, if needed, weekly doses
|
5 sequential days of treatment (1.5MIU/day subcutaneously) and, if needed, 1.5MIU/week doses until CABG surgery completed
Autres noms:
Standard care for patients with coronary artery disease undergoing CABG surgery
5 sequential days of treatment (2.0MIU/day subcutaneously) and, if needed, 2.0MIU/week doses until CABG surgery completed
Autres noms:
|
|
Expérimental: Low dose interleukin-2 at dose 2.0MIU
Commercially available aldesleukin with a UK marketing authorisation will be used and will be initially prepared as per SmPC.
Dose of 2.0MIU will be used for all daily and, if needed, weekly doses
|
5 sequential days of treatment (1.5MIU/day subcutaneously) and, if needed, 1.5MIU/week doses until CABG surgery completed
Autres noms:
Standard care for patients with coronary artery disease undergoing CABG surgery
5 sequential days of treatment (2.0MIU/day subcutaneously) and, if needed, 2.0MIU/week doses until CABG surgery completed
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Compare the differences in tissue-resident Treg gene signature in patients treated with ld-IL-2 compared to control
Délai: Time of surgery
|
Assessing Tregs from the various tissue beds and comparing differential gene expression markers for tissue healing and inflammation using sc/snRNA-sequencing technologies
|
Time of surgery
|
|
Comparing tissue-resident Tregs to peripheral blood Tregs from the same patient to assess the differential effect of ld-IL-2
Délai: Time of surgery
|
Comparing the tissue Tregs against blood Tregs from the same patient by comparing differential gene expression markers for tissue healing and inflammation using sc/snRNA-sequencing technologies and looking for differences between the two compartments.
|
Time of surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Difference in inflammatory T effector cells
Délai: Time of surgery
|
Comparing differential gene expression using sc/snRNA-sequencing technologies from isolated effector T cells between the 3 patient groups (control, 1.5MIU and 2.0MIU)
|
Time of surgery
|
|
Difference in other immune cells
Délai: Time of surgery
|
Comparing differential gene expression using sc/snRNA-sequencing technologies from other immune cells (e.g.
B cells) between the 3 patient groups (control, 1.5MIU and 2.0MIU)
|
Time of surgery
|
|
Comparing T cell receptor repertoire
Délai: Time of surgery
|
Comparing differences in T cell receptor (TCR) repertoire using TCR sequencing technologies between the 3 patient groups (control, 1.5MIU and 2.0MIU)
|
Time of surgery
|
|
Comparing tissue-resident immune cells to circulating immune cells
Délai: Time of surgery
|
Tissue-resident immune cells will be compared to peripheral/circulating immune cells from the same patient using sc/snRNA-seq technologies to compare the differential effect of ld-IL-2 on the two compartments.
|
Time of surgery
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Systemc biomarkers of inflammation and tissue damage
Délai: Time of surgery
|
Compare blood-based inflammation markers and assays between the three patient groups (control, 1.5MIU, 2.0MIU)
|
Time of surgery
|
|
Non-immune cells and cardiomyocytes
Délai: Time of surgery
|
Compare stromal and myocardial cells on sc/snRNA-seq technologies between the three patient groups (control, 1.5MIU, 2.0MIU)
|
Time of surgery
|
|
Characterise tissue-level gene signatures
Délai: Time of surgery
|
Tissue-level RNA expression will be evaluated on sc/snRNA-sequencing technologies
|
Time of surgery
|
|
Gut microbiota
Délai: Time of surgery
|
Compare stool-based analysis of microbiota between the three patient groups (control, 1.5MIU, 2.0MIU)
|
Time of surgery
|
|
Safety and tolerability of IL-2 in patients after acute MI undergoing CABG
Délai: Time of surgery
|
Safety and tolerability will be assessed by recording adverse events (AEs) and reviewing patient notes.
|
Time of surgery
|
Collaborateurs et enquêteurs
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies vasculaires
- Maladies cardiovasculaires
- Processus pathologiques
- Maladies cardiaques
- Infarctus
- Nécrose
- Artériosclérose
- Maladies artérielles occlusives
- Maladie coronarienne
- Ischémie myocardique
- Ischémie
- Conditions pathologiques, signes et symptômes
- Maladie de l'artère coronaire
- Infarctus du myocarde
- Administration des services de santé
- Qualité des soins de santé, accès et évaluation
- Qualité des soins de santé
- Indicateurs de qualité, soins de santé
- Standard de soins
- aldesleukin
Autres numéros d'identification d'étude
- A097309
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .